In this study, anti-CTLA-4 immunotherapy was combined with tremelimumab and exemestane and an elevation in the levels of peripheral CD4+ and CD8+ T cells, which express inducible co-stimulatory molecules (ICOS), was observed, suggesting a role for anti-CTLA-4 inhibitors in breast cancer treatment [104]. This evidence concerns the gene CD4 and breast carcinoma.